Market capitalization | $5.83b |
Enterprise Value | $7.37b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 33.22 |
P/S ratio (TTM) P/S ratio | 26.29 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 2,285.27% |
Revenue (TTM) Revenue | $221.90m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
19 Analysts have issued a BridgeBio Pharma Inc forecast:
19 Analysts have issued a BridgeBio Pharma Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 222 222 |
2,286%
2,286%
|
|
Gross Profit | 213 213 |
11,376%
11,376%
|
|
EBITDA | -571 -571 |
4%
4%
|
EBIT (Operating Income) EBIT | -577 -577 |
4%
4%
|
Net Profit | -536 -536 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Neil Kumar |
Employees | 730 |
Founded | 2015 |
Website | www.bridgebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.